Skip to main content
. Author manuscript; available in PMC: 2018 Sep 24.
Published in final edited form as: AIDS. 2017 Sep 24;31(15):2135–2145. doi: 10.1097/QAD.0000000000001586

Fig. 1. Mean time spent on suppressed and failed ART.

Fig. 1

Mean per person years spent suppressed (dark blue) and failed (red) on 1st-line ART, and suppressed (light blue) and failed (orange) 2nd-line ART for the rural setting (CLIN and POC-CD412, top) and urban setting (LAB-CD46, POC-CD46, and VL12, bottom). We include the time initially suppressed and failed, as well as time re-suppressed and failed after an adherence intervention. Strategies do not sum to total life expectancy since time spent lost to follow-up is not included. The subscript indicates test frequency (e.g., POC-CD412 denotes monitoring every 12 months with POC-CD4). CLIN, clinical ART monitoring strategy; POC-CD4, point-of-care CD4 ART monitoring strategy; LAB, laboratory CD4 ART monitoring strategy; VL, HIV RNA ART monitoring strategy; ART, antiretroviral therapy.